Register for email alerts and news feeds:
This journal | BMJ Group
rss
Heart 2005;91:1533-1536; doi:10.1136/hrt.2005.064493
Copyright © 2005 BMJ Publishing Group Ltd & British Cardiovascular Society

MINI-SYMPOSIUM

Recent advances in primary percutaneous intervention for acute myocardial infarction

E J Smith, A Mathur, M T Rothman

London Chest Hospital, London, UK

Correspondence to:
Correspondence to:
Professor Martin T Rothman
Cardiac Research Office, London Chest Hospital, Bonner Road, London E2 9JX, UK; martin.rothman@bartsandthelondon.nhs.uk

Abbreviations: AMI, acute myocardial infarction; BMS, bare metal stents; BMSC, bone marrow stem cell; DES, drug eluting stent; EMERALD, enhanced myocardial efficacy and recovery by aspiration of liberalized debris; EPC, endothelial progenitor cell; GpRA, glycoprotein IIb/IIIa receptor antagonist; ISR, in-stent restenosis; IVUS, intravascular ultrasound; LV, left ventricular; NFMI, non-fatal myocardial infarction; PPCI, primary percutaneous coronary intervention; SES, sirolimus eluting stent; STEMI, ST elevation myocardial infarction; TIMI, thrombolysis in myocardial infarction

Keywords: acute myocardial infarction; percutaneous coronary intervention; ST elevation myocardial infarction; STEMI

The first 150 words of the full text of this article appear below.

Interventional cardiology has evolved since the first studies comparing primary percutaneous intervention (PPCI) and intravenous thrombolysis for the treatment of ST segment elevation myocardial infarction (STEMI). Indeed it may now seem remarkable that in an era where abrupt vessel closure and restenosis occurred routinely in up to 8% and 40%, respectively,1,2 plain balloon angioplasty was able to demonstrate significant improvements in short and long term outcome relative to thrombolysis.3,4 This emphasises the prognostic importance of restoring effective flow in the culprit vessel as early as possible, for which PPCI has been highly effective from the outset. However, the corollary is that despite major advances in stent technology and adjuvant pharmacology since that time, the absolute outcome benefits of PPCI remain definite but modest.5 Here we put into context some of the recent advances in the field of PPCI, highlighting key questions that are yet to be answered, and speculate on . . . [Full text of this article]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.